| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Baculoviral IAP repeat-containing protein 3;6.3.2.-;Apoptosis inhibitor 2;API2;C-IAP2;IAP homolog C;Inhibitor of apoptosis protein 1;IAP-1;hIAP-1;hIAP1;RING finger protein 49;TNFR2-TRAF-signaling complex protein 1;BIRC3;API2, IAP1, MIHC, RNF49; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | E.coli-derived human cIAP2 recombinant protein (Position: M1-K191). Human cIAP2 shares 69.8% amino acid (aa) sequence identity with mouse cIAP2. |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Overview
This antibody is intended for detection of BIRC3 (Baculoviral IAP repeat-containing protein 3) in biological samples using common immunoassay formats. It is typically selected based on target identity, species reactivity, clonality/clone information, and detection modality.
Vendor notes: Boster Bio Anti-cIAP2/BIRC3 Antibody Picoband® catalog # PB9527. Tested in WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.
Key elements and design rationale
- Antibody format: Rabbit Polyclonal Rabbit IgG
- Immunogen / epitope context: E.coli-derived human cIAP2 recombinant protein (Position: M1-K191). Human cIAP2 shares 69.8% amino acid (aa) sequence identity with mouse cIAP2. (reported region: M1-K191).
- Molecular weight context: reported MW: 68 kDa; calculated MW: 68372 MW
- Reactivity: Human
- Applications: WB
As a polyclonal antibody, the reagent recognizes multiple epitopes on the target, which can improve detection robustness but may increase sensitivity to sample-dependent epitope changes.
Biological background
Baculoviral IAP repeat-containing protein 3; Baculoviral IAP repeat-containing protein 3. Baculoviral IAP repeat-containing protein 3 (also known as cIAP2) is a protein that in humans is encoded by the BIRC3 gene. cIAP2 is a member of the IAP family of proteins that inhibit apoptosis by binding to tumor necrosis factor receptor-associated factors TRAF1 and TRAF2, probably by interfering with activation of ICE-like proteases. The encoded protein inhibits apoptosis induced by serum deprivation but does not affect apoptosis resulting from exposure to menadione, a potent inducer of free radicals. It contains 3 baculovirus IAP repeats and a ring finger domain. Transcript variants encoding the same isoform have been identified. Functional note: Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin- protein ligase regulating NF-kappa-B signaling and regulates both canonical and non-canonical NF-kappa-B signaling by acting in opposite ions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin- protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase- independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. . Reported localization: Cytoplasm . Nucleus . Expression/tissue context: Highly expressed in fetal lung, and kidney. In the adult, expression is mainly seen in lymphoid tissues, including spleen, thymus and peripheral blood lymphocytes.
Research relevance and current trends
- Alzheimer's Disease: Researchers commonly examine how BIRC3 (Baculoviral IAP repeat-containing protein 3) relates to this theme using model systems and orthogonal readouts.
- Drug Metabolism: Researchers commonly examine how BIRC3 (Baculoviral IAP repeat-containing protein 3) relates to this theme using model systems and orthogonal readouts.
- Metabolic Signaling Pathways: Researchers commonly examine how BIRC3 (Baculoviral IAP repeat-containing protein 3) relates to this theme using model systems and orthogonal readouts.
Common research applications
- Western blotting: compare relative BIRC3 (Baculoviral IAP repeat-containing protein 3) levels across conditions; band patterns may reflect isoforms and processing.
Notes for experimental interpretation
- Specificity notes: No cross reactivity with other proteins.
- Cross-reactivity: No cross-reactivity with other proteins
- Family / similarity context: Belongs to the IAP family.
- Isoforms and PTMs: Apparent size and signal patterns can differ across splice isoforms, proteolytic processing, and post-translational modifications.
- Controls: Include an isotype control (as relevant), no-primary control for imaging, and orthogonal validation such as KD/KO samples when available.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.